Literature DB >> 27061924

Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia.

Toby A Eyre1, Christopher P Fox2, Paneesha Shankara3, Richard Went4, Anna H Schuh1,5,6.   

Abstract

Entities:  

Keywords:  zzm321990TP53zzm321990; B-cell prolymphocytic leukaemia; TP53 deletion; idelalisib; prolymphocytic leukaemia

Mesh：

Substances：

Year:  2016        PMID： 27061924     DOI： 10.1111/bjh.14066

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  3 in total

1.  Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion.

Authors:  H Coelho; M Badior; T Melo
Journal:  Case Rep Hematol       Date:  2017-07-27

Review 2.  PI3Kα in cardioprotection: Cytoskeleton, late Na+ current, and mechanism of arrhythmias.

Authors:  Pavel Zhabyeyev; Xueyi Chen; Bart Vanhaesebroeck; Gavin Y Oudit
Journal:  Channels (Austin)       Date:  2019-12       Impact factor: 2.581

3.  A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel).

Authors:  Toby A Eyre; Gavin Preston; Huseini Kagdi; Amin Islam; Toby Nicholson; Harry W Smith; Adam P Cursley; Heribert Ramroth; Guan Xing; Lin Gu; Nishanthan Rajakumaraswamy; Christopher Fegan
Journal:  Br J Haematol       Date:  2021-06-14       Impact factor: 6.998
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.